Nektr pharma’s mission is to develop therapies for multi-drug resistant and difficult to treat infections.
We are currently employing the technology in the areas of onychomycosis, anti-microbial resistance (AMR), dermatological challenges, nasal decontamination and medical device coatings.
Nektr Technologies has completed a Pharmaceutical Phase 3 Clinical Trial investigating A3IS’ efficacy against Onychomycosis in 38 participants. The Trial endpoint has now been reached and with outstanding results demonstrating the superiority of Nektrs antifungal formulation Mycosinate® against the European market leading product.
The prevalence of Onychomycosis, commonly known as fungal nail infection, increases steadily with age and is present in 50-60% of people over the age of 60 . With a growing aging population the onychomycosis market is expected to rapidly grow in the coming years.
Multi-Drug Resistant Pathogens
The National Institute of Health (NIH) has rigorously validated our technology A3IS against all critical and high priority WHO pathogens and biofilms with outstanding results. A3IS is a viable alternative to increasingly ineffective antibiotics.
The discovery of antibiotics has long been regarded as one of the most significant medical achievements saving millions of lives and enabling the performance of difficult medical procedures. The emergence and spread of global antimicrobial resistance is one of the greatest threats presently facing mankind.
A3IS has demonstrated exceptional anti-microbial efficacy against the most dangerous pathogenic organisms worldwide with no resistance observed.
The skin is the largest organ of the human body with many physiological and immunological functions. Wound infections and chronic wound management pose a significant challenge to health care systems globally, especially considering the timely threat of multi-drug resistant pathogens. Human skin also defines one’s physical appearance. It is therefore not surprising that significant correlations between visible dermatological skin conditions, psycho social functioning as well as quality of life exist.
With its antimicrobial and stimulatory properties, A3IS shows great promise as a potential alternative to antibiotics for the treatment of infected skin lacerations, chronic wounds and dermatological conditions.
Get in touch!
Do you have questions about Nektr or our technology? Connect with us using the details below or get in touch by filling out the form. We would be happy to answer your questions!
Finisklin Business & Technology Park,
Sligo, Ireland, F91 HF66